Compare KPTI & PRPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KPTI | PRPL |
|---|---|---|
| Founded | 2008 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Home Furnishings |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.6M | 89.8M |
| IPO Year | 2013 | N/A |
| Metric | KPTI | PRPL |
|---|---|---|
| Price | $6.50 | $0.79 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 1 |
| Target Price | ★ $22.17 | $1.00 |
| AVG Volume (30 Days) | 174.4K | ★ 300.7K |
| Earning Date | 11-03-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $142,530,000.00 | ★ $457,012,000.00 |
| Revenue This Year | $3.82 | N/A |
| Revenue Next Year | $3.18 | $12.69 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.51 | $0.56 |
| 52 Week High | $12.45 | $1.29 |
| Indicator | KPTI | PRPL |
|---|---|---|
| Relative Strength Index (RSI) | 55.05 | 50.04 |
| Support Level | $5.70 | $0.73 |
| Resistance Level | $7.48 | $0.87 |
| Average True Range (ATR) | 0.46 | 0.06 |
| MACD | 0.11 | 0.01 |
| Stochastic Oscillator | 49.08 | 43.46 |
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
Purple Innovation Inc is a comfort innovation company. The company designs, manufactures and sells a range of comfort technology offerings, including mattresses, a pillow, cushions, sheets, bed platforms and other products. The Company has one reportable segment that operates an omni-channel distribution which allows the Company to offer a seamless shopping experience to its customers across multiple sales channels. It sells its products through its direct-to-consumer e-commerce channels, retail brick-and-mortar wholesale partners, Purple showrooms, and third-party online retailers.